Related Experiment Video

Updated: Oct 2, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

Association between incidence of lipoprotein(a) positivity and coronary heart disease

S Vashisht1, H Wasir, L M Srivastava

  • 1Department of Biochemistry and Cardiology, All India Institute of Medical Sciences, New Delhi.

Indian Heart Journal
|July 1, 1992
PubMed

Insights

Lipoprotein(a) [LP(a)] presence is higher in coronary heart disease (CHD) patients compared to controls. LP(a) incidence varies by age and sex in patients, but not in controls, and is independent of serum lipid levels.

Area of Science:

  • Cardiovascular Medicine
  • Clinical Biochemistry
  • Lipidology

Background:

  • Coronary heart disease (CHD) remains a leading cause of mortality worldwide.
  • Lipoprotein(a) [LP(a)] is recognized as an independent risk factor for CHD.
  • Understanding the prevalence and associations of LP(a) in CHD patients is crucial for risk stratification.

Purpose of the Study:

  • To investigate the prevalence of LP(a) in patients with coronary heart disease (CHD) compared to a control group.
  • To examine the relationship between LP(a) presence, sex, age, and serum lipid profiles in CHD patients.

Main Methods:

  • Serum samples from 760 CHD patients and 167 controls were analyzed.
  • Polyacrylamide gel electrophoresis was used to assess lipoprotein profiles and detect LP(a).
  • Serum total cholesterol, triglyceride, and LDL/HDL ratios were evaluated.

Main Results:

  • A significantly higher proportion of CHD patients (both male and female) exhibited LP(a) compared to controls.
  • LP(a) incidence was independent of sex and age in controls, but increased marginally with age in female patients.
  • Male patients under 40 had a threefold higher incidence of LP(a) compared to females in the same age group.
  • No significant differences in serum lipid levels were observed between LP(a)-positive and LP(a)-negative patients.

Conclusions:

  • LP(a) positivity is more prevalent in individuals with coronary heart disease.
  • The presence of LP(a) in CHD patients shows distinct age and sex-related patterns.
  • LP(a) appears to be independent of common serum lipid variables (cholesterol, triglycerides, LDL/HDL ratio) in this patient cohort.

More Related Videos

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

High-Density Lipoprotein-Specific Phospholipid Efflux Assay07:08

High-Density Lipoprotein-Specific Phospholipid Efflux Assay

Published on: September 30, 2025

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...